Toxoplasma gondii in Solid Organ and Stem Cell Transplant: Prevention and Treatment

Guegan, Hélène; Robert‐Gangneux, Florence

doi:10.1007/978-3-030-01751-4_51-1

Cited by 2 publications

(3 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk for Toxoplasma varies by graft type, with a higher rate documented in mismatched heart recipients. Thus, prophylaxis should be guided by the serologic status of the donor and recipient [31]. Prophylaxis with TMP-SMX, primarily for heart recipients D+/R−, is recommended and can be considered for noncardiac D+/R− recipients [32 ▪ ].…”

Section: Candidate Screening and Recipient Prophylaxis: Prevention Of...mentioning

confidence: 99%

Prevention of infection and optimizing vaccination in the solid organ transplant candidate and recipient

Ryu

Narayanan

Bhatt

2021

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of review Infections can result in serious complications in solid organ transplant (SOT) patients. The need to remain up to date on recommendations on screening, vaccinations, and chemoprophylaxis is paramount in the management of SOT patients. The goal of this review is to provide an overview of current recommendations for the prevention of infections and optimization of vaccinations from the pretransplant through posttransplant periods. Recent findings There is an emphasis on thorough pretransplant evaluation to guide clinicians and pretransplant testing based on epidemiological and endemic risk factors. Additionally, recent studies on vaccine safety and efficacy of newer vaccine formulations in SOT recipients are addressed. Summary This review provides insight on updated recommendations for pretransplant screening, new data on vaccine optimization in SOT recipients and posttransplant prophylaxis. Further research is needed in order to improve preventive measures including screening tests, vaccines, and chemoprophylaxis.

show abstract

Section: Candidate Screening and Recipient Prophylaxis: Prevention Of...mentioning

confidence: 99%

Prevention of infection and optimizing vaccination in the solid organ transplant candidate and recipient

Ryu

Narayanan

Bhatt

2021

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

“…Although T. gondii infection remains asymptomatic in most individuals, it can progress to different clinical forms including ocular, gestational and neurological toxoplasmosis [6]. Toxoplasmosis is rare but possibly fatal in immunocompromised patients and can cause other diseases such as encephalitis, myocarditis, pneumonia, chorioretinitis and generalized lymphadenopathy [1,[7][8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

“…Recipients of donor organs can suffer the reactivation of previously latent infections after transplantation due to immunosuppression [8,[10][11][12][13][14][15]. Although the first report of toxoplasmosis in a liver graft recipient was published more than five decades ago, there are still few published studies that evaluated the transmission of T. gondii during this medical procedure [12,15,16].…”

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii Infection in Patients Submitted to Liver Transplantation

Pintos,

Pires,

Silva

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The liver has emerged as a frequent transplanted organ which can transmit T. gondii between seropositive donors and seronegative recipients. Associated with the immunosuppressive therapy of recipients, the presence of cysts in donor livers elevate the risk of severe toxoplasmosis in recipients. Objectives: The objective of the study was to verify the frequencies of positive serology in liver graft donors and their respective recipients, as well as to verify whether their clinical signs presented post-transplant are associated with the serological status of recipients. Patients and methods: All data on liver transplant recipients from 2008 to 2018 were obtained from the MVPeP electronic medical records of the Liver Transplant Service of FUNFARME/FAMERP. IgM and IgG anti-T. gondii antibody serology was investigated by chemiluminescence. According to the serological profile, four groups of recipients were assessed (G1: IgG-/IgM-; G2: IgG+/IgM-; G3: IgG+/IgM+, G4: IgG-/IgM+). Results: The numbers of recipients according to the serological profile groups were: G1: 20 (41.7%), G2: 26 (54.1%; G3: 2 (4.2%). No cases were found for G4. Post-transplant clinical manifestations such as fever without defined cause, lung nodules, headache, hepatosplenomegaly, encephalopathy and hepatitis (A, B and C) were reported in all groups. Conclusions: This study demonstrates that there is a high prevalence of T. gondii infection in liver recipients and, therefore, screening should be intensified. Furthermore, a high incidence of co-infection with hepatitis A was identified especially in patients who died in the post-transplant period.

show abstract

Toxoplasma gondii in Solid Organ and Stem Cell Transplant: Prevention and Treatment

Cited by 2 publications

References 97 publications

Prevention of infection and optimizing vaccination in the solid organ transplant candidate and recipient

Prevention of infection and optimizing vaccination in the solid organ transplant candidate and recipient

Toxoplasma gondii Infection in Patients Submitted to Liver Transplantation

Contact Info

Product

Resources

About